Zentalis Pharmaceuticals Inc
ZNTL
Company Profile
Business description
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Contact
10275 Science Center Drive
Suite 200
San DiegoCA92121
USAT: +1 858 263-4333
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
166
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,674.20 | 49.30 | -0.57% |
| CAC 40 | 7,589.66 | 36.21 | 0.48% |
| DAX 40 | 23,350.55 | 293.17 | 1.27% |
| Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
| FTSE 100 | 8,774.65 | 17.15 | -0.20% |
| HKSE | 23,516.76 | 13.72 | -0.06% |
| NASDAQ | 19,447.41 | 98.86 | -0.51% |
| Nikkei 225 | 38,252.46 | 150.77 | -0.39% |
| NZX 50 Index | 12,520.09 | 48.96 | -0.39% |
| S&P 500 | 5,967.84 | 13.03 | -0.22% |
| S&P/ASX 200 | 8,461.30 | 44.20 | -0.52% |
| SSE Composite Index | 3,365.07 | 5.17 | 0.15% |